Concepedia

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412

Paula de Melo Campos, João Agostinho Machado‐Neto, Renata Scopim‐Ribeiro, Valeria Visconte, Ali Tabarroki, Adriana Silva Santos Duarte, Flávia F.C. Barra, José Vassalo, Heesun J. Rogers, Irene Lorand‐Metze,

Leukemia Research · 2014 · 53 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

H Nagata, A S Worobec, Chang Kyu Oh et al. · Proceedings of the National Academy of Sciences · 1995 · 880 citations

, , +16

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients

Andrés C. García‐Montero · Blood · 2006 · 498 citations · Full text

, , +14

Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies

Marcus M. Schittenhelm, Sharon Shiraga, Arin Schroeder et al. · Cancer Research · 2006 · 467 citations

, , +16

The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor.

Robert Rottapel, Michael Reedijk, DE Williams et al. · Molecular and Cellular Biology · 1991 · 259 citations · Full text

, , +15

Comprehensive mutational profiling in advanced systemic mastocytosis

Juliana Schwaab, Susanne Schnittger, Karl Sotlar et al. · Blood · 2013 · 258 citations

, , +14